Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02025829 · ClinicalTrials.gov registry record

IL-17 Neutrophils in CF Lung Inflammation

A clinical trial of Cystic Fibrosis, sponsored by University Hospitals Cleveland Medical Center.

Completed
Registry status
14
Enrollment target
1
Study location

NCT02025829: Completed study of Cystic Fibrosis, sponsored by University Hospitals Cleveland Medical Center.

NCT02025829 is a study of Cystic Fibrosis that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 14 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02025829, a study of Cystic Fibrosis, has completed, sponsored by University Hospitals Cleveland Medical Center.

COMPLETED
Registry status
14 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether IL-17 polymorphonuclear leukocytes (PMNs) are central to the disease pathology in CF. This will be determined by demonstrating that IL-17 PMNs are present in the CF airway, correlate with lung function measures, and decrease in patients being treated with IV antibiotics for a pulmonary exacerbation.

Primary Outcome

In the Exacerbation/IV Antibiotics Cohort--Subjects will serve as their own controls. The percentage of neutrophils (in sputum) positive for IL-17 was determined by flow cytometry for each subject at the beginning and end of treatment for a pulmonary exacerbation. Sputum IL-17 neutrophil counts will be compared to the change in lung function (FEV1) as determined by spirometry (American Thoracic Society standards).

Conditions Studied

Study Locations (1)

Ohio

  • Rainbow Babies and Children's Hospital - Cleveland

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2014-02
Est. Completion 2014-12

What the finished NCT02025829 record still lists

NCT02025829 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions.

NCT02025829 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT02025829 about?

NCT02025829 is a clinical study titled "IL-17 Neutrophils in CF Lung Inflammation". The purpose of this study is to determine whether IL-17 polymorphonuclear leukocytes (PMNs) are central to the disease pathology in CF. This will be determined by demonstrating that IL-17 PMNs are present in the CF airway, correlate with lung function measures, and decrease in patients being treated...

What is the current status of trial NCT02025829?

This trial is currently completed. The enrollment target is 14 participants. The study started on 2014-02. Estimated completion is 2014-12.

What conditions does trial NCT02025829 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

Who is sponsoring clinical trial NCT02025829?

This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02025829 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02025829's enrollment target sits among peer trials

14 149th of 169 higher than 20 of 169 other Cystic Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02025829, the US trial registry maintained by the National Library of Medicine. NCT02025829 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.